Scholarlink

Purpose <p>Genomic classifiers are endorsed by guidelines and commonly used to inform prognosis in prostate cancer. We aimed to understand the distribution of genomic risk within the validated staging collaboration for cancer of the prostate (STAR-CAP) and propose a system integrating genomic and clinicopathologic risk. We hypothesized that genomic heterogeneity would have implications on risk estimates and may inform treatment decisions.</p> Materials and methods <p>Genomic risk was assessed using the Decipher genomic classifier in two separate multi-institutional, prospectively collected population-based registries: (1) Decipher Genomics Resource for Intelligent Discovery (GRID) [<i>n</i> = 50,891] and (2) Michigan Urological Surgery Improvement Collaborative (MUSIC-Decipher) [<i>n</i> = 1602]. The primary endpoint was estimated prostate cancer-specific mortality (PCSM), and secondary endpoint was distant metastasis (DM). Marginal risk estimates provided by STAR-CAP were combined with hazard ratios of Decipher to calculate integrated risk estimates.</p> Results <p>Median age and PSA was 68 years and 6.2 ng/mL in GRID, and 66 years and 10.5 ng/mL in MUSIC. The GRID population had 50.2%, 18.5%, and 31.4% with low-, intermediate-, and high-Decipher risk, compared to 48.0%, 16.2%, and 35.8% in MUSIC. Decipher-based genomic risk varied across STAR-CAP stages in both registries. Estimates of 10-year PCSM (0.1% to 48.8%) and DM (0.3%-72.9%) varied widely after integration of clinical-genomic risk. Use of an integrated Decipher-STAR-CAP system led to significant stage reclassification, including 23.4% upstaging and 45.6% downstaging at least one stage.</p> Conclusions <p>These findings suggest integration of genomic and clinicopathologic risk may lead to more nuanced risk assessment in prostate cancer and may help individualize treatment consideration.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Characterizing population-wide genomic risk distribution for development of a novel clinical-genomic risk system for prognostication in patients with clinically localized prostate cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月9日

查看全文
  • Udit Singhal,
  • Ralph Jiang,
  • James A. Proudfoot,
  • Elizabeth Chase,
  • Krithika Suresh,
  • Elai Davicioni,
  • Tudor Borza,
  • Michael J. Zelefsky,
  • Brian J. Davis,
  • Brad J. Stish,
  • R. Jeffrey Karnes,
  • Stephen J. Freedland,
  • Martha K. Terris,
  • William J. Aronson,
  • Matthew R. Cooperberg,
  • Fabio Y. Moraes,
  • Alejandro Berlin,
  • Curtiland Deville,
  • Nicholas G. Zaorsky,
  • Soumyajit Roy,
  • Angela Y. Jia,
  • Jonathan E. Shoag,
  • William C. Jackson,
  • Daniel E. Spratt,
  • Matthew Schipper,
  • Todd M. Morgan,
  • Robert T. Dess

摘要

Purpose

Genomic classifiers are endorsed by guidelines and commonly used to inform prognosis in prostate cancer. We aimed to understand the distribution of genomic risk within the validated staging collaboration for cancer of the prostate (STAR-CAP) and propose a system integrating genomic and clinicopathologic risk. We hypothesized that genomic heterogeneity would have implications on risk estimates and may inform treatment decisions.

Materials and methods

Genomic risk was assessed using the Decipher genomic classifier in two separate multi-institutional, prospectively collected population-based registries: (1) Decipher Genomics Resource for Intelligent Discovery (GRID) [n = 50,891] and (2) Michigan Urological Surgery Improvement Collaborative (MUSIC-Decipher) [n = 1602]. The primary endpoint was estimated prostate cancer-specific mortality (PCSM), and secondary endpoint was distant metastasis (DM). Marginal risk estimates provided by STAR-CAP were combined with hazard ratios of Decipher to calculate integrated risk estimates.

Results

Median age and PSA was 68 years and 6.2 ng/mL in GRID, and 66 years and 10.5 ng/mL in MUSIC. The GRID population had 50.2%, 18.5%, and 31.4% with low-, intermediate-, and high-Decipher risk, compared to 48.0%, 16.2%, and 35.8% in MUSIC. Decipher-based genomic risk varied across STAR-CAP stages in both registries. Estimates of 10-year PCSM (0.1% to 48.8%) and DM (0.3%-72.9%) varied widely after integration of clinical-genomic risk. Use of an integrated Decipher-STAR-CAP system led to significant stage reclassification, including 23.4% upstaging and 45.6% downstaging at least one stage.

Conclusions

These findings suggest integration of genomic and clinicopathologic risk may lead to more nuanced risk assessment in prostate cancer and may help individualize treatment consideration.